Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Jan 25;54(4):1443–1452. doi: 10.1128/AAC.01022-09

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2010, American Society for Microbiology

PMC Copyright notice

FIG. 1. — Linezolid twice-daily 0.5-h infusion of 600 mg over 48 h against S. aureus RN4220 and RN4220MutS2. Shown are the pharmacokinetic and pharmacodynamic effects of linezolid on S. aureus RN4220 (A1) and its mutant S. aureus RN4220MutS2 (B1) during the simulation of twice-daily 0.5-h infusion of 600 mg over 48 h in the in vitro PK-PD model (mean; n = 2). ⧫, PCp concentration-time curve; ▴, control growth curve; ▪, killing and regrowth curve. (A2 and B2) Emergence of linezolid-resistant mutants of S. aureus RN4220 (A2) and RN4220MutS2 (B2) during the corresponding simulations (mean percentage of viable counts; n = 2). Blue, control; green, resistant to 1.0 μg/ml; yellow, resistant to 2.0 μg/ml.